The first two authors contributed equally to this work Atorvastatin is an HMG-CoA reductase inhibitor used to treat hypercholesterolemic conditions associated with hypertension. This study aims to investigate the anti-inflammatory and neuroprotective effects of atorvastatin on peripheral neuropathic pain. Peripheral neuropathic pain was induced by chronic constriction injury (CCI) in Sprague-Dawley rats. Rats were divided into 3 groups including shamoperated, CCI, and atorvastatin-treated. Atorvastatin (10 mg/kg) or phosphate-buffered saline was orally administered for 2 weeks. All animals were assessed by neurobehavioral tests before surgery and at days 3,7,14 after surgery. Inflammatory and neuroprotective factors were evaluated by Western blot analysis. eNOS, COX2 and iNOS in the sciatic nerve were also studied using immunohistochemistry. Atorvastatin attenuated CCI-induced nociceptive sensitization and thermal hyperalgesia in a time-dependent manner. Atorvastatin improved CCI-induced neurobehavioral/inflammatory activity by inhibition of TGF-p, pIKB/lKB, NFKB, COX2, iNOS, EP1 and EP4 in the sciatic nerve. Atorvastatin was also found to increase neuroprotection factors pAktlAkt, eNOS and VEGF. Taken together, these data indicate that atorvastatin could protect the sciatic nerve against CCI-induced neuroinflammation and nociception.
CNS are termed neuroinflammation, and can lead to peripheral or central nerve damage and result in pathological nociceptive transmission. This condition is referred to as "neuropathic pain" (3) .
In contrast to neuropathic pain, there is an emerging idea that hyperlipidemia contributes to the development of diabetic neuropathy, which may explain the earlier incidence of diabetic neuropathy in individuals with type 2 compared to type 1 diabetes. Abnormalities in low-density lipoprotein (LDL) profiles were more closely related to diabetic neuropathy than hyperglycemia. A higher prevalence of hyperlipidemia than impaired glucose tolerance or hypertension suggests that dyslipidemia is an essential factor underlying nerve injury (4) (5) . The pathogenesis of damage to the pain mechanism is multifactorial and includes metabolic disturbances such as hyperglycemia, impaired glucose tolerance, dyslipidemia, oxidative stress, growth factor deficiencies, microvascular insufficiency, and autoimmune damage to nerve fibers (5) . Based on the previous findings, lipid lowering drugs may be beneficial in the treatment of diabetic neuropathy. Thus, we further sought to investigate whether stains, a class of drugs that lower plasma cholesterol levels, could affect neuropathic pain by mediating nerve injury-associated inflammatory responses.
Atrovastatin is one of a class of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors widely prescribed to reduce cholesterol levels in hyperlipidemic patients. Statins lower cholesterol production and promote hepatic removal of LDL cholesterol in serum. Aside from their conventional use reducing cholesterol levels, statins have been broadly used in many other clinical conditions, for instance cardiovascular (6) or cerebrovascular stroke (7) , and Alzheimer's disease (AD) (8) . There is growing evidence that statins may exert additional effects on neuroprotection, independently oftheireffects on cholesterol synthesis. The underlying neuroprotective mechanisms of statins include pleiotropic effects on modulation of nitric oxide synthase (NOS), vasoactive endothelial protection, antithrombosis, antioxidation, antiinflammation and immunomodulation (9, 10). Lee and colleagues pointed out that atorvastatin showed various neuroprotective abilities via activating pAkt in a sciatic nerve crush injury model (11) . Our research design first investigated the role of atorvastatin in a CCI model to find out whether atorvastatin would show similar neuroprotection functions in that model. The aim of this study is to investigate which molecular pathways are related to neuropathic pain in the CCI model and find out how atorvastatin attenuates this pain behavior.
MATERIALS' AND METHODS

Animals
Male Sprague-Dawley rats (n=60, 250-300 g), provided by the National Laboratory Animal Breeding and Research Center (Taipei, Taiwan), were used in the experiments. The rats were acclimatized for one week in the animal facility, in which temperature, humidity, and light cycle were controlled, and food and water were provided ad libitum. The study was approved by the Animal Care and Use Committee of the Kaohsiung Medical University.
Chronic constriction injury surgery
The bilateral chronic constriction injury surgery was modified according to the method described previously (12) . Briefly, 54 rats were anesthetized by intraperitoneal (i.p.) injection of 40 mg/kg sodium pentobarbital and the common sciatic nerve was exposed at the level of the middle thigh by blunt dissection through the bicep femoris muscle. Proximal to the sciatic trifurcation, approximately 7 mm of nerve was freed and 3 ligatures of 4-0 chromic catgut were placed around the sciatic nerve with l-mm intervals. The ligatures were tied until they elicited a brief twitch in the hind limb. This corresponded to blanching of the nerve and a significant reduction in nerve blood flow secondary to occlusion of the epineurial vasculature. The wound was then closed in layers. The other side of the sciatic nerve was manipulated under the same procedure. In sham-operated rats, the same surgical procedure was followed, but no ligatures were placed. Animals were maintained under standard colony conditions with food and water available ad libitum. xperimentaldesigns All animals were acclimatized to the laboratory environment for at least 1 hour before testing. Treatment for all rats consisted of oral atorvastatin (Lipitor®, Pfizer Ireland Pharmaceuticals Inc., Germany) 10 mg/kg once daily (13) for the treatment group (n=6) and sham group (n=6), starting on the day after surgery for 14 days. Eighteen animals (6 in each group) were sacrificed at day 3, day 7, and day 14 after surgery. The bilateral sciatic nerves from each group of rats were taken for further experiments.
Assessment ofneuropathic pain and behavioral testing
Allodynia (exaggerated response to normally nonnoxious stimuli) and hyperalgesia (decreased threshold to noxious stimuli) were evaluated in the sham, CCI and atorvastatin-treated groups. Paw withdrawal latency (PWL) was described previously to evaluate the thermal hyperalgesia (14) . Thermal hyperalgesia was assessed by placing the hind paw on a radiant heat source and measuring the PWL under low-intensity heat set to a cut-off time of 30 seconds using an IITC analgesiometer (IITC360, Woodland Hills, CA). Additionally, the withdrawal threshold was analyzed by a series of calibrated von Frey filaments. The rat was accommodated in a wire mesh cage (18 x25 x18 ern). The mechanical allodynia threshold was defined as the minimal force (g) initiating a withdrawal response. The entire procedure was repeated once more, and the average force evoking reliable withdrawals was taken as threshold.
Western blot analysis and protein extraction
All tissues at different time points were extracted, frozen in liquid nitrogen, and stored at -80°C. Each tissue sample was lysed in ice-cold (4°C) lysis buffer [50 mM Tris, pH 7.5, containing 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 0.2 mM EDTA, 10 mM NaF, 10 ug/ml, aprotinin, 1 ug/ml, leupeptin, 10 ug/ml, pepstatin, 0.4 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, and 1 mM sodium orthovanadate] and then centrifuged at 20,000x g for 30 min at 4°C. The supernatant from the pellet and retained western blot analysis of an equal volume of sample buffer (2% sodium dodecylsulphate (SDS), 10% glycerol, 0.1% bromophenol blue, 2% 2-mercaptoethanol and 50 mM Tris-HCL, pH 7.2) was added to the sample, which was then loaded onto 12% SDS-polyacrylamide gel and transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore) using blotting apparatus. The membrane was blocked with 5% milk in TBS-T for 1 hour then incubated with TGF-( 1:500 dilution; Millipore, Billerica, MA, USA), Akt (1: 1000 dilution; Cell Signaling Technology, Danvers, MA, USA), phosphate Akt (pAkt) (Ser473, 1:500 dilution; Cell Signaling Technology, Danvers, MA, USA), NFKB p65 (1:500 dilution; Spring, Pleasanton, CA, USA), IKB, eNOS, iNOS (1: 1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA), phosphate IKB (pIKB), VEGF (1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA), COX-2 (1:1000 dilution; Abeam, London, UK), EPl, EP4 (1:500 dilution; cayman, Ann Arbor, MI, USA), and~-actin (1:2000 dilution; Sigma, MO, USA). After secondary antibody conjugated with HRP (1:5000 dilutions in 5% milk) for 1 hour, the signals on membrane were detected using ECL-plus luminal solution and exposed to X-ray film for autoradiogram.
Immunohistochemistry detection ofeNOS, COX-2 and iNOS
Sciatic nerves were removed, fixed in 4% paraformaldehyde, and then transferred to a 30% sucrose solution overnight at 4°C. The specimens were embedded in tissue freezing medium to decrease the variation in immunohistochemical procedures (15) . Sections (10 urn) were cut together on a cryostat (Leica CM1900) at -20°C and processed for immunofluorescence. The sections were incubated overnight at 4°C with primary antibody anti-eNOS (BD transduction Laboratories, Lexington, KY), anti-COX-2 (Abeam, London, UK) and anti-iNOS (Santa Cruz Biotechnology, Santa Cruz, CA). Following repeated washings, the slides were incubated with biotin-conjugated secondary antibody. After probing, the avidin-peroxidase complex was added, and finally, 3, 3-diaminobenzidine substrate was utilized for color development. The slides were then counterstained with hematoxylin.
Statistical analyses
All the values were expressed as mean ± S.E.M. for six animals per group. The behavior data and the Western blot results were analyzed by one-way analysis of variance (ANOVA). When appropriate, a Tukey-Kramer pairwise comparison was used for post hoc analysis. Pvalues <0.05 were considered statistically significant.
RESULTS
Atorvastatin on mechanical-and thermal-induced hyperalgesia
CCI-induced inflammations led to significant thermal and mechanical hypersensitivities with a reduction in the thermal withdrawal latency ( Daysafter operation L.W. eHU ET AL. Those results demonstrated that atorvastatin could improve the thermal hyperalgesia and mechanical allodynia behaviors induced by CCI.
Atorvastatin increased VEGF, pAkt/Akt and eNOS proteins
After CCI, VEGF, pAkt/Akt and eNOS proteins were measured together with other possibly injuryrelated proteins in the sciatic nerve. The timecourse alterations of VEGF, pAkt/Akt and eNOS expression after CCI were shown ( Fig. 2A ). There was a significant increase of VEGF expression after atorvastatin treatment at day 3, day 7 and day 14 (Fig. 2B ). The expression of Akt, also known as protein kinase B, was measured by the ratio of pAkt to total Akt. pAkt expression significantly decreased in sciatic nerve at days 7 and 14 following injury. After atorvastatin (10 mg/kg, p.o.) administration, the increase of pAkt/Akt expression was observed at day 7 following CCI, then increased peak at day 14 (Fig. 2C) . A significant decrease of eNOS expression was observed at day 14 after CCI and it was significantly increased after atorvastatin at day 7 and day 14 (Fig. 2D) .
Atorvastatin decreased TGF-~, pIKE/IKE, NFKE, COX-2, EP I, EP4 and iNOS proteins
After CCI, the time-course alterations of TGF-~, piKE/IKE, nuclear NFKE, COX-2, EP1, EP4 and iNOS expression after CCI were shown (Fig. 3A) . CCI led to significantly increased expressions of TGF-~at day 3, day 7 and day 14 after CCI. After atorvastatin (10 mg/kg, p.o.) administration, TGFexpression attenuated significantly at all time points compared with the CCI group (Fig. 3B ). IKE activity was measured by the ratio of cytoplasmic plKE/IKB, a key step of NFKE activation, which showed significant increases at each time point after CCI compared with the sham group. Atorvastatin significantly reduced the expression of cytoplasmic plKE/IKE from day 3 to day 14 after CCI (Fig. 3C ). Nuclear NFKE protein was also decreased from day 3 to day 14 after atorvastatin treatment (Fig. 3D) . Notably, the COX-2 protein was markedly increased after CCI compared with the sham group. After atorvastatin, COX-2 expression was dramatically decreased compared with the CCI group. Even at day 14, the atorvastatin-treated group still showed much lower COX-2 expression than the sham group, indicating its powerful anti-inflammatory potential (Fig. 3E) . Meanwhile, the increase in iNOS protein was significant after CCI and this inflammatory protein was reduced by atorvastatin (Fig. 3F) . The EPland EP4 proteins were also significantly increased after CCI and decreased after atorvastatin administration (Fig. 3, G and H) .
Atorvastatin increased eNOS, and decreased COX-2 and iNOS immunohistochemical localization
To further confirm that the decrease of eNOS, and activation of COX-2 and iNOS were involved in the peripheral nerve injury induced by CCI, immunohistochemical stainingwas used.Wefoundthat CCI induced a rapid decrease in eNOS, and increase in COX-2 and iNOS expression in the sciatic nerve at day 3. Atorvastatin (10 mg/kg, p.o.) significantly increased CCI-induced eNOS downregulation (Fig.  4) , and attenuated CCI-induced COX-2 and iNOS upregulationat day 7 and day 14 ( Figs. 5 and 6 ). 
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DISCUSSION
We first demonstrated that atorvastatin decreased CCI-induced upregulating expression of neuroinflammation factors in the sciatic nerve.
The major findings in this study are as follows: I) Atorvastatin could attenuate neuropathic pain behavior in a rat CCI model. The drug reduced the severity of thermal hyperalgesia. However, the anti-hyperalgesic effect was not obvious until day 7 after atorvastatin administration. 2) Atorvastatin causes upregulation of expression of pAkt, VEGF, and eNOS proteins in the sciatic nerve in a timedependent manner that corresponds to the production and persistence of the behavioral hyperalgesia. 3) Atorvastatin causes downregulation of expression ofTGF-p, pIKB/IKB, NFKB, COX-2, EPI, EP4 and iNOS proteins in the sciatic nerve. These findings provide evidence for a novel mechanism involved in neuropathic pain induced by nerve injury, and a novel role for atorvastatin in treating nerve injury and associated neuropathic pain. The CCI animal model is an excellent model for the study of peripheral neuropathic pain. Allowing the observation of behavioral changes corresponds to thermal hyperalgesia and mechanical allodynia under various stimuli. These two types of behavior represent twq different hyperalgesia sensitization phenomena. Primary hyperalgesia is mediated in part by sensitization of primary afferent nociceptors reflected by increased responses to heat stimuli. Secondary hyperalgesia is due to sensitization in the central nervous system and it is characterized by hyperalgesia to mechanical stimuli (16) . In this study, we investigated the antiallodynic and antihyperalgesic effects of atorvastatin and the possible mechanisms involved in attenuating hypersensitivity. To explore possible mechanisms for the antihyperalgesic and antiallodynic effects of atorvastatin in neuropathic rats, we quantified the level of TGF-p, COX-2, iNOS, EPI and EP4 in the sciatic nerve. We also examined the effects of atorvastatin on neuroprotection by measuring the expression of pAkt, eNOS, and VEGF. It has been shown that statins can activate several neuroprotective molecules or mechanisms. Although the cellular signaling pathways of neurogenesis are largely unknown, the PI3K1Akt pathway has been indicated to increase neurogenesis (17) . The neurogenic effects of simvastatin may also involve the survival-related PI3K1Akt pathway (18) . Akt is expressed at high levels during neurogenesis (19) . From these studies we may infer that neuroprotection and neurogenesis effects exerted by statins come from activation of the Akt pathway and its downstream signals. This supports the conclusion that atorvastatin has neuroprotective effects in CCI rats.
VEGF shows some neurotrophic and neuroprotective effects (20) . Other studies further nucleus • -• indicate that VEGF directly (21) or indirectly (22) increases the effects of neurogenesis factor. VEGF plays a critical. role in angiogenesis, neurogenesis and neuropathy. Although VEGF was initially discovered in the vascular system, recently its role in the nervous system has been studied intensely. Aside from neurogenesis, VEGF can protect nerves from some kinds of damage, probably by activating the VEGF-2 receptor/PI3K1Akt pathway (23) . In this study, we found that VEGF expression decreased gradually following CCI; however, VEGF expression increased after atorvastatin administration. Thus we deduce that atorvastatin exerts its neuroprotectvie effect by increasing VEGF expression. Activation of VEGF gene transcription subsequently increases the production of eNOS (24) . The angiogenic effect was defective in eNOS knock-out mice (25) . Hashiguchi and colleagues also confirmed that eNOS exerted neuroprotection under ischemic conditions (26) . We deduce that when peripheral nerve injury occurs, atorvastatin can increase vascular permeability and oxygenation, speed regeneration, and shorten the recovery period in damaged nervous tissue (27) .
Neuro rotection
TGF-~plays an important role during the period of developmental cell death in the nervous system. TGF-~activates NFJ43 via TAKI/MEK pathway (28) . Activation of the NFKB signaling pathway relies upon signal-dependent phosphorylation and degradation of the IKB proteins that results in subsequent nuclear translocation of the NFKB dimer (29) . NFKB expression could be induced after CNS inflammation or nervous stem cell proliferation (30) . In addition, intrathecal administration of the NFKB inhibitor pyrrolidinedithiocarbamate also attenuated allodynia in a model of neuropathic pain induced by sciatic nerve inflammation (31) . From our findings, we further confirmed that the NFKB inhibition did attenuate neuropathic pain induced by a rat CCI model (32) .
Inflammatory hypemociceptive mediators, such as prostaglandins (PGs), considered to be directly acting on their specific metabotropic receptors present on the primary sensory neurons (33) . PGE2, a pro-inflammatory prostanoid, exerts its effect by acting via PGE receptor subtypes, EPI to EP4 (34) . Evidence shows that whether from the genetic or pharmacological point of view, generation of neuropathic pain is closely related to the activation of spinal microglia by PGE2 (34) . However, it is little described in the peripheral nerve system. In the present study, we have shown that atorvastatin downregulates the expression of EP 1 and EP4 in rat sciatic nerve, suggesting it might have peripheral anti-inflammatory and analgesic actions.
To our knowledge, this is the first study to demonstrate the effects and action mechanisms of atorvastatin in the treatment of neuropathic pain in the CCI model, which mimics human peripheral mononeuropathy. Our results demonstrate that atorvastatin achieves its neuroprotective effect in part by increasing VEGF activity and upregulating downstreamAkt and eNOS expression, subsequently leading to increased vascular permeability and accelerating functional recovery of damaged nervous tissues. Atorvastatin also exerts its effect by inhibiting TGF-~activity, causing decreased expression of intracellular piKE, and preventing NFKEtranslocation into nucleus, leading to decreased expression of downstream iNOS, COX-2 and PGE2, and finally elimination of neuroinflammation ( Fig.  7) . In conclusion, this study provides the evidence that atorvastatin could be a novel class of agent for the treatment of peripheral neuropathic pain.
